Exheus, company specialising in RNA analysis, a member of CataloniaBio & HealthTech, has secured a 900,000 euro funding round. The investment will help it to start its international expansion.

The round was led by Decelera Ventures and also involved WA4Steam, NextGen Venture Partners, as well as other investors through the Capital Cell platform, with an investment of 650,000 euros. This has been complemented with another 250,000 euros from a funding line provided by the Centre for Technological and Industrial Development (Cdti) of the Ministry of Science and Innovation. In parallel, they received a grant of 50,000 euros from EIT Health.

Exheus will use the investment to initiate international expansion in Europe, create a commercial structure that will allow it to access the healthcare system in European countries and work on regularising the legal requirements necessary for the company to be able to operate on an international scale. At the same time, it plans to digitise the product following a B2B approach so that healthcare professionals can directly access the patient's results and assess the RNA test.

Exheus was founded in 2020 as a spinoff of the Complex Diseases Genomics Research Group of the Sant Pau Hospital Research Institute and the Universitat Politècnica de Catalunya. The company analyses the expression of all the genes in the human body present in the blood transcriptome to be able to detect and correct anomalies that affect a person's health. Since its foundation, the company has raised more than 1.4 million euros.